Related Experiment Videos
Initial experience combining methotrexate with biologic agents for treating rheumatoid arthritis
1Department of Medicine, University of Alabama at Birmingham, AL, USA.
The Journal of Rheumatology. Supplement
|March 1, 1996
Summary
Combining methotrexate (MTX) with biologic agents for rheumatoid arthritis (RA) is being explored. Early trials evaluated MTX with an anti-CD4 antibody in patients with refractory RA, with potential for other combinations.
Area of Science:
- Rheumatology
- Immunology
- Pharmacology
Background:
- The combination of traditional disease-modifying antirheumatic drugs (DMARDs) like methotrexate (MTX) with biologic agents for rheumatoid arthritis (RA) treatment has been limited.
- Rheumatoid arthritis management often requires combination therapies to achieve optimal patient outcomes.
Purpose of the Study:
- To review the potential of combining methotrexate (MTX) with biologic agents for rheumatoid arthritis (RA) treatment.
- To discuss the evaluation of MTX combined with a depleting anti-CD4 monoclonal antibody (cM-T412) in clinical trials for refractory RA.
Main Methods:
- Review of existing literature and clinical trial data.
- Analysis of phase I and II trial results for MTX and cM-T412 combination therapy.
- Exploration of the therapeutic rationale for combining MTX with various biologic agents.
Main Results:
- The combination of MTX and cM-T412 has been assessed in phase I and II clinical trials for patients with refractory RA.
- Preliminary data suggests potential efficacy and safety profiles for this specific combination, warranting further investigation.
Conclusions:
- The combination of methotrexate with biologic agents represents a potential therapeutic strategy for rheumatoid arthritis.
- Further research is needed to fully elucidate the benefits and risks of combining MTX with different biologic agents in RA management.